CA2758823A1 - Protein phosphatase 2a-activating agents - Google Patents

Protein phosphatase 2a-activating agents Download PDF

Info

Publication number
CA2758823A1
CA2758823A1 CA2758823A CA2758823A CA2758823A1 CA 2758823 A1 CA2758823 A1 CA 2758823A1 CA 2758823 A CA2758823 A CA 2758823A CA 2758823 A CA2758823 A CA 2758823A CA 2758823 A1 CA2758823 A1 CA 2758823A1
Authority
CA
Canada
Prior art keywords
chroman
enyl
yloxy
dimethyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2758823A
Other languages
English (en)
French (fr)
Inventor
Ching-Shih Chen
Dasheng Wang
Samuel K. Kulp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of CA2758823A1 publication Critical patent/CA2758823A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/723,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA2758823A 2009-04-13 2010-04-13 Protein phosphatase 2a-activating agents Abandoned CA2758823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16875909P 2009-04-13 2009-04-13
US61/168,759 2009-04-13
PCT/US2010/030799 WO2010120711A1 (en) 2009-04-13 2010-04-13 Protein phosphatase 2a-activating agents

Publications (1)

Publication Number Publication Date
CA2758823A1 true CA2758823A1 (en) 2010-10-21

Family

ID=42981438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2758823A Abandoned CA2758823A1 (en) 2009-04-13 2010-04-13 Protein phosphatase 2a-activating agents

Country Status (6)

Country Link
US (1) US8461362B2 (enExample)
EP (1) EP2419414A4 (enExample)
JP (1) JP2012523458A (enExample)
AU (1) AU2010236655A1 (enExample)
CA (1) CA2758823A1 (enExample)
WO (1) WO2010120711A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2414205T3 (es) * 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
WO2010120711A1 (en) 2009-04-13 2010-10-21 The Ohio State University Research Foundation Protein phosphatase 2a-activating agents
EP2418948B1 (en) * 2009-04-17 2013-09-04 The Ohio State University Research Foundation Antiadhesion agents
WO2012074960A2 (en) 2010-11-29 2012-06-07 The Ohio State University Research Foundation Fty720-derived anticancer agents
US9220706B2 (en) 2012-06-01 2015-12-29 National Institutes Of Health (Nih) Inhibition of leukemic stem cells by PP2A activating agents
WO2016109825A1 (en) * 2014-12-31 2016-07-07 Fluidigm Canada Inc. Structured biological samples for analysis by mass cytometry
EP3313819A1 (en) * 2015-06-23 2018-05-02 Case Western Reserve University Compositions and methods for treating cancer
EP3334725B1 (en) 2015-08-10 2025-04-23 Dana-Farber Cancer Institute, Inc. Bromodomain and extra terminal (bet) inhibitor and a protein phosphatase 2a (pp2a) activator for treating bet inhibitor resistant cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2680749A (en) * 1951-12-01 1954-06-08 Eastman Kodak Co Water-soluble tocopherol derivatives
DE2822324C3 (de) * 1978-05-22 1981-02-26 Basf Ag, 6700 Ludwigshafen Herstellung von Vitamin-E-Trockenpulver
JPS59222415A (ja) 1983-05-31 1984-12-14 Kuraray Co Ltd 免疫調節剤
US4751224A (en) * 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis
SK282225B6 (sk) * 1995-12-28 2001-12-03 Welfide Corporation Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
RU2232758C2 (ru) * 1998-09-23 2004-07-20 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием
US6703384B2 (en) * 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6770672B1 (en) * 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
AU2001236805B2 (en) * 2000-02-11 2005-07-14 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
JP2002121132A (ja) * 2000-08-09 2002-04-23 Showa Denko Kk 発がん抑制剤および発がん抑制方法
CA2455547A1 (en) * 2001-07-27 2003-02-13 University Of Rochester Use of vitamin e succinate and antiandrogen combination
US6858227B1 (en) * 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US20050215531A1 (en) * 2002-05-16 2005-09-29 Thomas Baumruker Use of edg receptor binding agents in cancer
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
CA2583087C (en) * 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
CN101346346B (zh) * 2005-12-15 2012-08-22 田边三菱制药株式会社 胺化合物及其医药用途
US20080009545A1 (en) * 2006-02-21 2008-01-10 The Ohio State University Research Foundation Anticancer agents
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
CA2660880C (en) 2006-08-17 2015-10-13 Betty C. Soliven Treatment of inflammatory diseases
NZ575920A (en) * 2006-09-15 2012-08-31 Stephen John Ralph Pro-oxidant anti-cancer compounds
JP4481316B2 (ja) * 2007-01-09 2010-06-16 株式会社エヌ・ティ・ティ・ドコモ ユーザ装置および送信方法
BRPI0813683A2 (pt) * 2007-06-14 2019-09-24 Mitsubishi Tanabe Pharma Corp composto amina e uso farmacêutico do mesmo
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
WO2010120711A1 (en) 2009-04-13 2010-10-21 The Ohio State University Research Foundation Protein phosphatase 2a-activating agents
EP2418948B1 (en) 2009-04-17 2013-09-04 The Ohio State University Research Foundation Antiadhesion agents

Also Published As

Publication number Publication date
WO2010120711A1 (en) 2010-10-21
US8461362B2 (en) 2013-06-11
AU2010236655A1 (en) 2011-11-17
US20100267673A1 (en) 2010-10-21
EP2419414A1 (en) 2012-02-22
JP2012523458A (ja) 2012-10-04
EP2419414A4 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
US8461362B2 (en) Protein phosphatase 2A-activating agents
Yan et al. Synthesis, evaluation, and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo
Nambiar et al. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1
Patil et al. Phosphonooxymethyl prodrug of triptolide: Synthesis, physicochemical characterization, and efficacy in human colon adenocarcinoma and ovarian cancer xenografts
Tseng et al. Synthesis and anti-inflammatory evaluations of β-lapachone derivatives
Johnson et al. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells
US9757350B2 (en) Small molecule inhibitors of replication protein A that also act synergistically with cisplatin
US20160185771A1 (en) Conjugate of Benzofuranone and Indole or Azaindole, and Preparation and Uses Thereof
Wang et al. Inhibition of heat shock induction of heat shock protein 70 and enhancement of heat shock protein 27 phosphorylation by quercetin derivatives
Cerón-Romero et al. In vitro and in silico PTP-1B inhibition and in vivo antidiabetic activity of semisynthetic moronic acid derivatives
Pirali et al. Identification of a potent phosphoinositide 3‐kinase pan inhibitor displaying a strategic carboxylic acid group and development of its prodrugs
AU2015314772A1 (en) Compositions and methods for treatment of prostate carcinoma
US7026346B2 (en) Compounds and methods for inducing apoptosis in proliferating cells
EP2418948B1 (en) Antiadhesion agents
JP2015098492A (ja) チアゾリジンジオンエネルギー制限模倣剤
WO2012087889A2 (en) Dna methylation inhibitors
AU2007217810B2 (en) Anticancer agents
US8519007B2 (en) Use certain diterpene compounds in the treatment of androgen receptor-associated diseases
US10188743B2 (en) Cytisine-linked isoflavonoid antineoplastic agents for the treatment of cancer
EP2909171B1 (fr) Composés 3,4-bis(catéchol)pyrrole n-substitués, leur préparation et utilisation dans le traitement du cancer
KR101207981B1 (ko) 호르몬 불응성 전립선암의 예방 또는 치료용 약제학적 조성물 및 그의 스크리닝 방법
WO2016160819A1 (en) Method for the treatment of nf1-or ras-associated disorders
US20140031388A1 (en) Akt inactivation by tocopheryl derivatives
US20060142368A1 (en) Compounds and methods for inducing apoptosis in proliferating cells
US20250170154A1 (en) Genistein phosphate derivatives

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160413